Alzamend Neuro is a biotechnology business based in the US. Alzamend Neuro shares (ALZN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.67 – an increase of 1.21% over the previous week. Alzamend Neuro employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.67 |
|---|---|
| 52-week range | $0.63 - $7.30 |
| 50-day moving average | $0.82 |
| 200-day moving average | $1.55 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-134.51 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.67 from 2025-05-02
| 1 week (2025-04-25) | -1.47% |
|---|---|
| 1 month (2025-04-04) | -31.84% |
| 3 months (2025-02-05) | -43.70% |
| 6 months (2024-11-05) | -59.15% |
| 1 year (2024-05-03) | -7.71% |
|---|---|
| 2 years (2023-05-03) | -99.11% |
| 3 years (2022-05-03) | 168 |
| 5 years (2020-05-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -106.08% |
| Return on equity TTM | -1092.96% |
| Profit margin | 0% |
| Book value | $0.60 |
| Market Capitalization | $4.4 million |
TTM: trailing 12 months
We're not expecting Alzamend Neuro to pay a dividend over the next 12 months.
You may also wish to consider:
Alzamend Neuro's shares were split on a 1:10 basis on 15 July 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alzamend Neuro shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Alzamend Neuro shares which in turn could have impacted Alzamend Neuro's share price.
Over the last 12 months, Alzamend Neuro's shares have ranged in value from as little as $0.627 up to $7.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alzamend Neuro's is -0.192. This would suggest that Alzamend Neuro's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Alzamend Neuro has bucked the trend.
To put Alzamend Neuro's beta into context you can compare it against those of similar companies.
Alzamend Neuro, Inc. , a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. .
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.